logo transparent gif
top_left_edge top_white_spacer top_right_edge
Home Latest Stock Forum Topics MyCorner - Personal Stocks Porfolio Stock Lists Forex Investor Insights Investment News Investor Research & Links Dynamic Stock Charting FREE Registration About Us top spacer top spacer
 User Password Auto-Login
Enter Stock
 
righttip
branding

Back
First   1-20 of 118   Older>   Last  
Latest Forum Topics / Venture    Last:17.67    +0.2  Post Reply
2022 Venture Corporation - A Year Of Recovery
tongphlp
Supreme
21-Mar-2023 09:06     
 
tongphlp About Contact  Quote this Post!  
  x 1
  x 0

 Alert Admin 		report good results = price drop
report bad results = price drop like crazy
analyst downgrade = price drop like crazy
analyst upgrade = price also drop
SGX is like that

MambaFinancial89      ( Date: 20-Mar-2023 18:45) Posted:

Nowadays sentiment shifts very quickly... 

MBULLISH      ( Date: 20-Mar-2023 17:10) Posted:

If world recession come due to contagious from banks collapse and high interest rate ,
Can q at $7 to $8
No hurry to buy now due to bad sentiments


 Useful To Me  Not Useful To Me
tongphlp
Supreme
21-Mar-2023 08:57     
 
tongphlp About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		yup...that' s why banks cannot collapse..

MBULLISH      ( Date: 20-Mar-2023 17:10) Posted:

If world recession come due to contagious from banks collapse and high interest rate ,
Can q at $7 to $8
No hurry to buy now due to bad sentiments

 Useful To Me  Not Useful To Me


MambaFinancial89
Senior
20-Mar-2023 18:45     
 
MambaFinancial89 About Contact  Quote this Post! Style: Fundamental  
  x 0
  x 0

 Alert Admin 		Nowadays sentiment shifts very quickly... 

MBULLISH      ( Date: 20-Mar-2023 17:10) Posted:

If world recession come due to contagious from banks collapse and high interest rate ,
Can q at $7 to $8
No hurry to buy now due to bad sentiments

 Useful To Me  Not Useful To Me
MBULLISH
Elite
20-Mar-2023 17:10     
 
MBULLISH About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		If world recession come due to contagious from banks collapse and high interest rate ,
Can q at $7 to $8
No hurry to buy now due to bad sentiments
 Useful To Me  Not Useful To Me
tongphlp
Supreme
20-Mar-2023 16:37     
 
tongphlp About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		13 is also near..

tongphlp      ( Date: 14-Mar-2023 11:14) Posted:

at this rate, 15 is hitting soon and then 14...

tongphlp      ( Date: 08-Mar-2023 09:22) Posted:

15 coming..
 Useful To Me  Not Useful To Me


tongphlp
Supreme
14-Mar-2023 11:14     
 
tongphlp About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		at this rate, 15 is hitting soon and then 14...

tongphlp      ( Date: 08-Mar-2023 09:22) Posted:

15 coming...

tongphlp      ( Date: 07-Mar-2023 10:02) Posted:

what BS - talk is cheap. sell down to below 17 and yet positive.
 Useful To Me  Not Useful To Me
tongphlp
Supreme
13-Mar-2023 16:31     
 
tongphlp About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		exactly!

Venture is hopeless....

limkt009      ( Date: 08-Mar-2023 09:31) Posted:

Stupid, right!!!

tongphlp      ( Date: 07-Mar-2023 10:17) Posted:

DBS Group Research analyst Ling Lee Keng, who retained her & ldquo buy& rdquo call, also kept her target price unchanged at $20.10, which is pegged to a five-year average P/E of 15x on blended FY2023/FY2024 earnings.

Upgrade but price not moving
Downgrade and price get beaten
 Useful To Me  Not Useful To Me
limkt009
Master
08-Mar-2023 09:31     
 
limkt009 About Contact  Quote this Post! Style: Flexible   Mood: happy
Yells: "Watch your front, grab $$$$$$$$ at your own time"
  x 0
  x 0

 Alert Admin 		Stupid, right!!!

tongphlp      ( Date: 07-Mar-2023 10:17) Posted:

DBS Group Research analyst Ling Lee Keng, who retained her & ldquo buy& rdquo call, also kept her target price unchanged at $20.10, which is pegged to a five-year average P/E of 15x on blended FY2023/FY2024 earnings.

Upgrade but price not moving
Downgrade and price get beaten

Joelton      ( Date: 07-Mar-2023 09:57) Posted:

Analysts positive on Venture Corp' s FY2022 earnings despite management' s cautious outlook for FY2023
Analysts are all keeping their &ldquo add&rdquo or &ldquo buy&rdquo calls on Venture Corporation V03 0.18%   as the company&rsquo s results for the FY2022 ended Dec 31, 2022, exceeded the expectations of the consensus.
 
CGS-CIMB Research analysts William Tng and Izabella Tan have kept their &ldquo add&rdquo call with an unchanged target price of $20.10 as Venture Corp&rsquo s FY2022 results came &ldquo in line&rdquo with their expectations at 103% of their full-year forecasts. The analysts&rsquo target price is based on a 22-year average forward P/E of 15.2x.
 
&ldquo We note that FY2022 results bring Venture&rsquo s performance benchmark back to the pre-pandemic levels,&rdquo write Tng and Tan. &ldquo Profitability wise, Venture&rsquo s pre-tax and net profit margin were relatively stable at 11.6%/9.6% in FY2022 versus 11.6%/10.0% in FY2021.&rdquo
 
In their report, the analysts note Venture&rsquo s concern for the short-term future on the back of the uncertain global macroeconomic and geopolitical environment. However, they are positive on the company&rsquo s longer-term prospects with its strategy to continue its sharp focus on deepening its partnerships with customers to create outstanding innovative products and services.
 
Tng and Tan are also positive about Venture&rsquo s strategy to scale up its businesses.
 
That said, the ongoing supply disruptions are a key concern, as well as the labour shortages and weakening global economic outlook. On the other hand, new product launches by customers and improvements in component availability is deemed to be an upside risk.
 
DBS Group Research analyst Ling Lee Keng, who retained her &ldquo buy&rdquo call, also kept her target price unchanged at $20.10, which is pegged to a five-year average P/E of 15x on blended FY2023/FY2024 earnings.
 
Based on her estimates, Venture Corp&rsquo s FY2022 revenue stood 3.6% above her projections while its net profit stood 1.6% higher than expected.
 
&ldquo The revenue growth reflects robust customer demand in several technology domains and new product introductions during the year. Healthcare & wellness, life science & genomics and test & measurement instrumentation technology domains were significant contributors to the overall performance,&rdquo she writes.
 
She adds that the group&rsquo s FY2022 results reflected a &ldquo commendable&rdquo net margin of 9.6% despite the challenging environment and inflationary pressures.
 
Like her peers at CGS-CIMB, Ling sees near-term pressures due to the macroeconomic slowdown that has affected demand though Venture could be less affected than its peers given its exposure to higher-end consumer products where demand in less volatile.
 
Furthermore, Venture&rsquo s products, especially in life sciences, healthcare & wellness and medical, also have a longer shelf life, Ling adds.
 
&ldquo Going forward, Venture will continue to invest in the development of new differentiating capabilities in multiple technology domains to pave the way for future growth. Key areas of focus include domains with structural long-term growth potential such as life sciences, medical and healthcare,&rdquo she writes.
 
In the meantime, the analyst has lowered her earnings estimates for the FY2023 and FY2024 by 4% each to account for the cautious near-term outlook.
 
&ldquo As a leading global provider of technology services, products and solutions, Venture is best known for its superior and differentiating capabilities in engineering, manufacturing and research and development (R& D) and providing high-mix, high-value, and complex manufacturing,&rdquo says Ling. &ldquo With its diversified product mix and blue-chip customers base, Venture is in a sweet spot to capture new opportunities in emerging technology domains.&rdquo
 
Key risks, in her view, are the global economic slowdown, the weakening of Venture&rsquo s clients&rsquo end demand, as well as the weakening of the US dollar (USD), which could dampen revenue growth.
 
For more stories about where money flows, click here for Capital Section
 
Maybank Securities analyst Jarick Seet has kept his &ldquo buy&rdquo call with an unchanged target price of $20.20 as Venture&rsquo s revenue and earnings for the 4QFY2022 exceeded his estimates.
 
The company&rsquo s dividend of 75 cents for the FY2022 also stood in line with Seet&rsquo s expectations.
 
As Venture expects FY2023 to be a challenging year due to the macro headwinds, Seet has cut his FY2023 and FY2024 earnings by 7% and 11% respectively to reflect the slower growth expected.
 
However, he believes in the longer-term outlook for the company. &ldquo [Venture&rsquo s] management remains confident of its long-term prospects and continues to deepen its partnership with customers to create outstanding innovative products and to scale up its businesses,&rdquo he notes.
 
To this end, Venture remains one of Seet&rsquo s preferred picks for the Singapore technology sector due to its &ldquo excellent execution track record even in tough times&rdquo .
 
Seet&rsquo s unchanged target price is based on an FY2023 P/E of 16.2x.
 
RHB Group Research analyst Alfie Yeo has also kept his &ldquo buy&rdquo call but with a lower target price of $22 from $23.30 previously. Yeo is the only analyst to tweak his target price, which is based on 16x of Venture&rsquo s FY2023 earnings, and 0.5 standard deviation (s.d.) from its historical P/E mean.
 
The lower target price is based on a recalibration of his valuation peg. It has also factored in a reduction of his earnings estimates for the FY2024.
 
&ldquo We re-peg our target P/E to 16x from 19x, which is at a more reasonable +0.5 s.d. from its four-year historical P/E mean (previously +2 s.d.),&rdquo he says.
 
&ldquo As Venture has an environmental, social and governance (ESG) score of three out of four &ndash which is on par with our country median &ndash we ascribe a 0% ESG discount or premium to our target price,&rdquo he adds.
 
Like the rest of his peers, Venture&rsquo s FY2022 earnings came within Yeo&rsquo s full-year estimates. As such, his earnings forecasts for FY2023-FY2024 are &ldquo marginally unchanged&rdquo .
 
&ldquo [However], we did trim [our] FY2024 earnings [estimate] by about 5% to $433 million, and moderated its expected growth rate from to 8% y-o-y from 13% y-o-y,&rdquo he writes.
 
&ldquo Our higher revenue estimate stems from better-than-expected revenue traction and customer demand, while our margin assumptions have been pared down to higher operating costs, i.e. near the current run rate,&rdquo he adds.
 
As Venture&rsquo s FY2022 earnings normalised to pre-pandemic levels, Yeo is remaining &ldquo upbeat&rdquo on the company&rsquo s prospects. &ldquo Management&rsquo s strategy to offer differing solutions remains intact,&rdquo he says.
 
In addition to the changed valuation peg, Yeo&rsquo s lowered target price also factors in his reduced FY2024 earnings estimates.
 
&ldquo Downside risks to our forecasts include decelerating demand in the global environment, resource shortages including component, labour and supply chain constraints,&rdquo he says.
 Useful To Me  Not Useful To Me


tongphlp
Supreme
08-Mar-2023 09:22     
 
tongphlp About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		15 coming...

tongphlp      ( Date: 07-Mar-2023 10:02) Posted:

what BS - talk is cheap. sell down to below 17 and yet positive..

Joelton      ( Date: 07-Mar-2023 09:57) Posted:

Analysts positive on Venture Corp' s FY2022 earnings despite management' s cautious outlook for FY2023
Analysts are all keeping their &ldquo add&rdquo or &ldquo buy&rdquo calls on Venture Corporation V03 0.18%   as the company&rsquo s results for the FY2022 ended Dec 31, 2022, exceeded the expectations of the consensus.
 
CGS-CIMB Research analysts William Tng and Izabella Tan have kept their &ldquo add&rdquo call with an unchanged target price of $20.10 as Venture Corp&rsquo s FY2022 results came &ldquo in line&rdquo with their expectations at 103% of their full-year forecasts. The analysts&rsquo target price is based on a 22-year average forward P/E of 15.2x.
 
&ldquo We note that FY2022 results bring Venture&rsquo s performance benchmark back to the pre-pandemic levels,&rdquo write Tng and Tan. &ldquo Profitability wise, Venture&rsquo s pre-tax and net profit margin were relatively stable at 11.6%/9.6% in FY2022 versus 11.6%/10.0% in FY2021.&rdquo
 
In their report, the analysts note Venture&rsquo s concern for the short-term future on the back of the uncertain global macroeconomic and geopolitical environment. However, they are positive on the company&rsquo s longer-term prospects with its strategy to continue its sharp focus on deepening its partnerships with customers to create outstanding innovative products and services.
 
Tng and Tan are also positive about Venture&rsquo s strategy to scale up its businesses.
 
That said, the ongoing supply disruptions are a key concern, as well as the labour shortages and weakening global economic outlook. On the other hand, new product launches by customers and improvements in component availability is deemed to be an upside risk.
 
DBS Group Research analyst Ling Lee Keng, who retained her &ldquo buy&rdquo call, also kept her target price unchanged at $20.10, which is pegged to a five-year average P/E of 15x on blended FY2023/FY2024 earnings.
 
Based on her estimates, Venture Corp&rsquo s FY2022 revenue stood 3.6% above her projections while its net profit stood 1.6% higher than expected.
 
&ldquo The revenue growth reflects robust customer demand in several technology domains and new product introductions during the year. Healthcare & wellness, life science & genomics and test & measurement instrumentation technology domains were significant contributors to the overall performance,&rdquo she writes.
 
She adds that the group&rsquo s FY2022 results reflected a &ldquo commendable&rdquo net margin of 9.6% despite the challenging environment and inflationary pressures.
 
Like her peers at CGS-CIMB, Ling sees near-term pressures due to the macroeconomic slowdown that has affected demand though Venture could be less affected than its peers given its exposure to higher-end consumer products where demand in less volatile.
 
Furthermore, Venture&rsquo s products, especially in life sciences, healthcare & wellness and medical, also have a longer shelf life, Ling adds.
 
&ldquo Going forward, Venture will continue to invest in the development of new differentiating capabilities in multiple technology domains to pave the way for future growth. Key areas of focus include domains with structural long-term growth potential such as life sciences, medical and healthcare,&rdquo she writes.
 
In the meantime, the analyst has lowered her earnings estimates for the FY2023 and FY2024 by 4% each to account for the cautious near-term outlook.
 
&ldquo As a leading global provider of technology services, products and solutions, Venture is best known for its superior and differentiating capabilities in engineering, manufacturing and research and development (R& D) and providing high-mix, high-value, and complex manufacturing,&rdquo says Ling. &ldquo With its diversified product mix and blue-chip customers base, Venture is in a sweet spot to capture new opportunities in emerging technology domains.&rdquo
 
Key risks, in her view, are the global economic slowdown, the weakening of Venture&rsquo s clients&rsquo end demand, as well as the weakening of the US dollar (USD), which could dampen revenue growth.
 
For more stories about where money flows, click here for Capital Section
 
Maybank Securities analyst Jarick Seet has kept his &ldquo buy&rdquo call with an unchanged target price of $20.20 as Venture&rsquo s revenue and earnings for the 4QFY2022 exceeded his estimates.
 
The company&rsquo s dividend of 75 cents for the FY2022 also stood in line with Seet&rsquo s expectations.
 
As Venture expects FY2023 to be a challenging year due to the macro headwinds, Seet has cut his FY2023 and FY2024 earnings by 7% and 11% respectively to reflect the slower growth expected.
 
However, he believes in the longer-term outlook for the company. &ldquo [Venture&rsquo s] management remains confident of its long-term prospects and continues to deepen its partnership with customers to create outstanding innovative products and to scale up its businesses,&rdquo he notes.
 
To this end, Venture remains one of Seet&rsquo s preferred picks for the Singapore technology sector due to its &ldquo excellent execution track record even in tough times&rdquo .
 
Seet&rsquo s unchanged target price is based on an FY2023 P/E of 16.2x.
 
RHB Group Research analyst Alfie Yeo has also kept his &ldquo buy&rdquo call but with a lower target price of $22 from $23.30 previously. Yeo is the only analyst to tweak his target price, which is based on 16x of Venture&rsquo s FY2023 earnings, and 0.5 standard deviation (s.d.) from its historical P/E mean.
 
The lower target price is based on a recalibration of his valuation peg. It has also factored in a reduction of his earnings estimates for the FY2024.
 
&ldquo We re-peg our target P/E to 16x from 19x, which is at a more reasonable +0.5 s.d. from its four-year historical P/E mean (previously +2 s.d.),&rdquo he says.
 
&ldquo As Venture has an environmental, social and governance (ESG) score of three out of four &ndash which is on par with our country median &ndash we ascribe a 0% ESG discount or premium to our target price,&rdquo he adds.
 
Like the rest of his peers, Venture&rsquo s FY2022 earnings came within Yeo&rsquo s full-year estimates. As such, his earnings forecasts for FY2023-FY2024 are &ldquo marginally unchanged&rdquo .
 
&ldquo [However], we did trim [our] FY2024 earnings [estimate] by about 5% to $433 million, and moderated its expected growth rate from to 8% y-o-y from 13% y-o-y,&rdquo he writes.
 
&ldquo Our higher revenue estimate stems from better-than-expected revenue traction and customer demand, while our margin assumptions have been pared down to higher operating costs, i.e. near the current run rate,&rdquo he adds.
 
As Venture&rsquo s FY2022 earnings normalised to pre-pandemic levels, Yeo is remaining &ldquo upbeat&rdquo on the company&rsquo s prospects. &ldquo Management&rsquo s strategy to offer differing solutions remains intact,&rdquo he says.
 
In addition to the changed valuation peg, Yeo&rsquo s lowered target price also factors in his reduced FY2024 earnings estimates.
 
&ldquo Downside risks to our forecasts include decelerating demand in the global environment, resource shortages including component, labour and supply chain constraints,&rdquo he says.
 Useful To Me  Not Useful To Me
tongphlp
Supreme
07-Mar-2023 10:17     
 
tongphlp About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		DBS Group Research analyst Ling Lee Keng, who retained her & ldquo buy& rdquo call, also kept her target price unchanged at $20.10, which is pegged to a five-year average P/E of 15x on blended FY2023/FY2024 earnings.

Upgrade but price not moving
Downgrade and price get beaten

Joelton      ( Date: 07-Mar-2023 09:57) Posted:

Analysts positive on Venture Corp' s FY2022 earnings despite management' s cautious outlook for FY2023
Analysts are all keeping their &ldquo add&rdquo or &ldquo buy&rdquo calls on Venture Corporation V03 0.18%   as the company&rsquo s results for the FY2022 ended Dec 31, 2022, exceeded the expectations of the consensus.
 
CGS-CIMB Research analysts William Tng and Izabella Tan have kept their &ldquo add&rdquo call with an unchanged target price of $20.10 as Venture Corp&rsquo s FY2022 results came &ldquo in line&rdquo with their expectations at 103% of their full-year forecasts. The analysts&rsquo target price is based on a 22-year average forward P/E of 15.2x.
 
&ldquo We note that FY2022 results bring Venture&rsquo s performance benchmark back to the pre-pandemic levels,&rdquo write Tng and Tan. &ldquo Profitability wise, Venture&rsquo s pre-tax and net profit margin were relatively stable at 11.6%/9.6% in FY2022 versus 11.6%/10.0% in FY2021.&rdquo
 
In their report, the analysts note Venture&rsquo s concern for the short-term future on the back of the uncertain global macroeconomic and geopolitical environment. However, they are positive on the company&rsquo s longer-term prospects with its strategy to continue its sharp focus on deepening its partnerships with customers to create outstanding innovative products and services.
 
Tng and Tan are also positive about Venture&rsquo s strategy to scale up its businesses.
 
That said, the ongoing supply disruptions are a key concern, as well as the labour shortages and weakening global economic outlook. On the other hand, new product launches by customers and improvements in component availability is deemed to be an upside risk.
 
DBS Group Research analyst Ling Lee Keng, who retained her &ldquo buy&rdquo call, also kept her target price unchanged at $20.10, which is pegged to a five-year average P/E of 15x on blended FY2023/FY2024 earnings.
 
Based on her estimates, Venture Corp&rsquo s FY2022 revenue stood 3.6% above her projections while its net profit stood 1.6% higher than expected.
 
&ldquo The revenue growth reflects robust customer demand in several technology domains and new product introductions during the year. Healthcare & wellness, life science & genomics and test & measurement instrumentation technology domains were significant contributors to the overall performance,&rdquo she writes.
 
She adds that the group&rsquo s FY2022 results reflected a &ldquo commendable&rdquo net margin of 9.6% despite the challenging environment and inflationary pressures.
 
Like her peers at CGS-CIMB, Ling sees near-term pressures due to the macroeconomic slowdown that has affected demand though Venture could be less affected than its peers given its exposure to higher-end consumer products where demand in less volatile.
 
Furthermore, Venture&rsquo s products, especially in life sciences, healthcare & wellness and medical, also have a longer shelf life, Ling adds.
 
&ldquo Going forward, Venture will continue to invest in the development of new differentiating capabilities in multiple technology domains to pave the way for future growth. Key areas of focus include domains with structural long-term growth potential such as life sciences, medical and healthcare,&rdquo she writes.
 
In the meantime, the analyst has lowered her earnings estimates for the FY2023 and FY2024 by 4% each to account for the cautious near-term outlook.
 
&ldquo As a leading global provider of technology services, products and solutions, Venture is best known for its superior and differentiating capabilities in engineering, manufacturing and research and development (R& D) and providing high-mix, high-value, and complex manufacturing,&rdquo says Ling. &ldquo With its diversified product mix and blue-chip customers base, Venture is in a sweet spot to capture new opportunities in emerging technology domains.&rdquo
 
Key risks, in her view, are the global economic slowdown, the weakening of Venture&rsquo s clients&rsquo end demand, as well as the weakening of the US dollar (USD), which could dampen revenue growth.
 
For more stories about where money flows, click here for Capital Section
 
Maybank Securities analyst Jarick Seet has kept his &ldquo buy&rdquo call with an unchanged target price of $20.20 as Venture&rsquo s revenue and earnings for the 4QFY2022 exceeded his estimates.
 
The company&rsquo s dividend of 75 cents for the FY2022 also stood in line with Seet&rsquo s expectations.
 
As Venture expects FY2023 to be a challenging year due to the macro headwinds, Seet has cut his FY2023 and FY2024 earnings by 7% and 11% respectively to reflect the slower growth expected.
 
However, he believes in the longer-term outlook for the company. &ldquo [Venture&rsquo s] management remains confident of its long-term prospects and continues to deepen its partnership with customers to create outstanding innovative products and to scale up its businesses,&rdquo he notes.
 
To this end, Venture remains one of Seet&rsquo s preferred picks for the Singapore technology sector due to its &ldquo excellent execution track record even in tough times&rdquo .
 
Seet&rsquo s unchanged target price is based on an FY2023 P/E of 16.2x.
 
RHB Group Research analyst Alfie Yeo has also kept his &ldquo buy&rdquo call but with a lower target price of $22 from $23.30 previously. Yeo is the only analyst to tweak his target price, which is based on 16x of Venture&rsquo s FY2023 earnings, and 0.5 standard deviation (s.d.) from its historical P/E mean.
 
The lower target price is based on a recalibration of his valuation peg. It has also factored in a reduction of his earnings estimates for the FY2024.
 
&ldquo We re-peg our target P/E to 16x from 19x, which is at a more reasonable +0.5 s.d. from its four-year historical P/E mean (previously +2 s.d.),&rdquo he says.
 
&ldquo As Venture has an environmental, social and governance (ESG) score of three out of four &ndash which is on par with our country median &ndash we ascribe a 0% ESG discount or premium to our target price,&rdquo he adds.
 
Like the rest of his peers, Venture&rsquo s FY2022 earnings came within Yeo&rsquo s full-year estimates. As such, his earnings forecasts for FY2023-FY2024 are &ldquo marginally unchanged&rdquo .
 
&ldquo [However], we did trim [our] FY2024 earnings [estimate] by about 5% to $433 million, and moderated its expected growth rate from to 8% y-o-y from 13% y-o-y,&rdquo he writes.
 
&ldquo Our higher revenue estimate stems from better-than-expected revenue traction and customer demand, while our margin assumptions have been pared down to higher operating costs, i.e. near the current run rate,&rdquo he adds.
 
As Venture&rsquo s FY2022 earnings normalised to pre-pandemic levels, Yeo is remaining &ldquo upbeat&rdquo on the company&rsquo s prospects. &ldquo Management&rsquo s strategy to offer differing solutions remains intact,&rdquo he says.
 
In addition to the changed valuation peg, Yeo&rsquo s lowered target price also factors in his reduced FY2024 earnings estimates.
 
&ldquo Downside risks to our forecasts include decelerating demand in the global environment, resource shortages including component, labour and supply chain constraints,&rdquo he says.
 Useful To Me  Not Useful To Me
tongphlp
Supreme
07-Mar-2023 10:02     
 
tongphlp About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		what BS - talk is cheap. sell down to below 17 and yet positive..

Joelton      ( Date: 07-Mar-2023 09:57) Posted:

Analysts positive on Venture Corp' s FY2022 earnings despite management' s cautious outlook for FY2023
Analysts are all keeping their &ldquo add&rdquo or &ldquo buy&rdquo calls on Venture Corporation V03 0.18%   as the company&rsquo s results for the FY2022 ended Dec 31, 2022, exceeded the expectations of the consensus.
 
CGS-CIMB Research analysts William Tng and Izabella Tan have kept their &ldquo add&rdquo call with an unchanged target price of $20.10 as Venture Corp&rsquo s FY2022 results came &ldquo in line&rdquo with their expectations at 103% of their full-year forecasts. The analysts&rsquo target price is based on a 22-year average forward P/E of 15.2x.
 
&ldquo We note that FY2022 results bring Venture&rsquo s performance benchmark back to the pre-pandemic levels,&rdquo write Tng and Tan. &ldquo Profitability wise, Venture&rsquo s pre-tax and net profit margin were relatively stable at 11.6%/9.6% in FY2022 versus 11.6%/10.0% in FY2021.&rdquo
 
In their report, the analysts note Venture&rsquo s concern for the short-term future on the back of the uncertain global macroeconomic and geopolitical environment. However, they are positive on the company&rsquo s longer-term prospects with its strategy to continue its sharp focus on deepening its partnerships with customers to create outstanding innovative products and services.
 
Tng and Tan are also positive about Venture&rsquo s strategy to scale up its businesses.
 
That said, the ongoing supply disruptions are a key concern, as well as the labour shortages and weakening global economic outlook. On the other hand, new product launches by customers and improvements in component availability is deemed to be an upside risk.
 
DBS Group Research analyst Ling Lee Keng, who retained her &ldquo buy&rdquo call, also kept her target price unchanged at $20.10, which is pegged to a five-year average P/E of 15x on blended FY2023/FY2024 earnings.
 
Based on her estimates, Venture Corp&rsquo s FY2022 revenue stood 3.6% above her projections while its net profit stood 1.6% higher than expected.
 
&ldquo The revenue growth reflects robust customer demand in several technology domains and new product introductions during the year. Healthcare & wellness, life science & genomics and test & measurement instrumentation technology domains were significant contributors to the overall performance,&rdquo she writes.
 
She adds that the group&rsquo s FY2022 results reflected a &ldquo commendable&rdquo net margin of 9.6% despite the challenging environment and inflationary pressures.
 
Like her peers at CGS-CIMB, Ling sees near-term pressures due to the macroeconomic slowdown that has affected demand though Venture could be less affected than its peers given its exposure to higher-end consumer products where demand in less volatile.
 
Furthermore, Venture&rsquo s products, especially in life sciences, healthcare & wellness and medical, also have a longer shelf life, Ling adds.
 
&ldquo Going forward, Venture will continue to invest in the development of new differentiating capabilities in multiple technology domains to pave the way for future growth. Key areas of focus include domains with structural long-term growth potential such as life sciences, medical and healthcare,&rdquo she writes.
 
In the meantime, the analyst has lowered her earnings estimates for the FY2023 and FY2024 by 4% each to account for the cautious near-term outlook.
 
&ldquo As a leading global provider of technology services, products and solutions, Venture is best known for its superior and differentiating capabilities in engineering, manufacturing and research and development (R& D) and providing high-mix, high-value, and complex manufacturing,&rdquo says Ling. &ldquo With its diversified product mix and blue-chip customers base, Venture is in a sweet spot to capture new opportunities in emerging technology domains.&rdquo
 
Key risks, in her view, are the global economic slowdown, the weakening of Venture&rsquo s clients&rsquo end demand, as well as the weakening of the US dollar (USD), which could dampen revenue growth.
 
For more stories about where money flows, click here for Capital Section
 
Maybank Securities analyst Jarick Seet has kept his &ldquo buy&rdquo call with an unchanged target price of $20.20 as Venture&rsquo s revenue and earnings for the 4QFY2022 exceeded his estimates.
 
The company&rsquo s dividend of 75 cents for the FY2022 also stood in line with Seet&rsquo s expectations.
 
As Venture expects FY2023 to be a challenging year due to the macro headwinds, Seet has cut his FY2023 and FY2024 earnings by 7% and 11% respectively to reflect the slower growth expected.
 
However, he believes in the longer-term outlook for the company. &ldquo [Venture&rsquo s] management remains confident of its long-term prospects and continues to deepen its partnership with customers to create outstanding innovative products and to scale up its businesses,&rdquo he notes.
 
To this end, Venture remains one of Seet&rsquo s preferred picks for the Singapore technology sector due to its &ldquo excellent execution track record even in tough times&rdquo .
 
Seet&rsquo s unchanged target price is based on an FY2023 P/E of 16.2x.
 
RHB Group Research analyst Alfie Yeo has also kept his &ldquo buy&rdquo call but with a lower target price of $22 from $23.30 previously. Yeo is the only analyst to tweak his target price, which is based on 16x of Venture&rsquo s FY2023 earnings, and 0.5 standard deviation (s.d.) from its historical P/E mean.
 
The lower target price is based on a recalibration of his valuation peg. It has also factored in a reduction of his earnings estimates for the FY2024.
 
&ldquo We re-peg our target P/E to 16x from 19x, which is at a more reasonable +0.5 s.d. from its four-year historical P/E mean (previously +2 s.d.),&rdquo he says.
 
&ldquo As Venture has an environmental, social and governance (ESG) score of three out of four &ndash which is on par with our country median &ndash we ascribe a 0% ESG discount or premium to our target price,&rdquo he adds.
 
Like the rest of his peers, Venture&rsquo s FY2022 earnings came within Yeo&rsquo s full-year estimates. As such, his earnings forecasts for FY2023-FY2024 are &ldquo marginally unchanged&rdquo .
 
&ldquo [However], we did trim [our] FY2024 earnings [estimate] by about 5% to $433 million, and moderated its expected growth rate from to 8% y-o-y from 13% y-o-y,&rdquo he writes.
 
&ldquo Our higher revenue estimate stems from better-than-expected revenue traction and customer demand, while our margin assumptions have been pared down to higher operating costs, i.e. near the current run rate,&rdquo he adds.
 
As Venture&rsquo s FY2022 earnings normalised to pre-pandemic levels, Yeo is remaining &ldquo upbeat&rdquo on the company&rsquo s prospects. &ldquo Management&rsquo s strategy to offer differing solutions remains intact,&rdquo he says.
 
In addition to the changed valuation peg, Yeo&rsquo s lowered target price also factors in his reduced FY2024 earnings estimates.
 
&ldquo Downside risks to our forecasts include decelerating demand in the global environment, resource shortages including component, labour and supply chain constraints,&rdquo he says.
 Useful To Me  Not Useful To Me
Joelton
Supreme
07-Mar-2023 09:57     
 
Joelton About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin
Analysts positive on Venture Corp' s FY2022 earnings despite management' s cautious outlook for FY2023
Analysts are all keeping their &ldquo add&rdquo or &ldquo buy&rdquo calls on Venture Corporation V03 0.18%   as the company&rsquo s results for the FY2022 ended Dec 31, 2022, exceeded the expectations of the consensus.
 
CGS-CIMB Research analysts William Tng and Izabella Tan have kept their &ldquo add&rdquo call with an unchanged target price of $20.10 as Venture Corp&rsquo s FY2022 results came &ldquo in line&rdquo with their expectations at 103% of their full-year forecasts. The analysts&rsquo target price is based on a 22-year average forward P/E of 15.2x.
 
&ldquo We note that FY2022 results bring Venture&rsquo s performance benchmark back to the pre-pandemic levels,&rdquo write Tng and Tan. &ldquo Profitability wise, Venture&rsquo s pre-tax and net profit margin were relatively stable at 11.6%/9.6% in FY2022 versus 11.6%/10.0% in FY2021.&rdquo
 
In their report, the analysts note Venture&rsquo s concern for the short-term future on the back of the uncertain global macroeconomic and geopolitical environment. However, they are positive on the company&rsquo s longer-term prospects with its strategy to continue its sharp focus on deepening its partnerships with customers to create outstanding innovative products and services.
 
Tng and Tan are also positive about Venture&rsquo s strategy to scale up its businesses.
 
That said, the ongoing supply disruptions are a key concern, as well as the labour shortages and weakening global economic outlook. On the other hand, new product launches by customers and improvements in component availability is deemed to be an upside risk.
 
DBS Group Research analyst Ling Lee Keng, who retained her &ldquo buy&rdquo call, also kept her target price unchanged at $20.10, which is pegged to a five-year average P/E of 15x on blended FY2023/FY2024 earnings.
 
Based on her estimates, Venture Corp&rsquo s FY2022 revenue stood 3.6% above her projections while its net profit stood 1.6% higher than expected.
 
&ldquo The revenue growth reflects robust customer demand in several technology domains and new product introductions during the year. Healthcare & wellness, life science & genomics and test & measurement instrumentation technology domains were significant contributors to the overall performance,&rdquo she writes.
 
She adds that the group&rsquo s FY2022 results reflected a &ldquo commendable&rdquo net margin of 9.6% despite the challenging environment and inflationary pressures.
 
Like her peers at CGS-CIMB, Ling sees near-term pressures due to the macroeconomic slowdown that has affected demand though Venture could be less affected than its peers given its exposure to higher-end consumer products where demand in less volatile.
 
Furthermore, Venture&rsquo s products, especially in life sciences, healthcare & wellness and medical, also have a longer shelf life, Ling adds.
 
&ldquo Going forward, Venture will continue to invest in the development of new differentiating capabilities in multiple technology domains to pave the way for future growth. Key areas of focus include domains with structural long-term growth potential such as life sciences, medical and healthcare,&rdquo she writes.
 
In the meantime, the analyst has lowered her earnings estimates for the FY2023 and FY2024 by 4% each to account for the cautious near-term outlook.
 
&ldquo As a leading global provider of technology services, products and solutions, Venture is best known for its superior and differentiating capabilities in engineering, manufacturing and research and development (R& D) and providing high-mix, high-value, and complex manufacturing,&rdquo says Ling. &ldquo With its diversified product mix and blue-chip customers base, Venture is in a sweet spot to capture new opportunities in emerging technology domains.&rdquo
 
Key risks, in her view, are the global economic slowdown, the weakening of Venture&rsquo s clients&rsquo end demand, as well as the weakening of the US dollar (USD), which could dampen revenue growth.
 
For more stories about where money flows, click here for Capital Section
 
Maybank Securities analyst Jarick Seet has kept his &ldquo buy&rdquo call with an unchanged target price of $20.20 as Venture&rsquo s revenue and earnings for the 4QFY2022 exceeded his estimates.
 
The company&rsquo s dividend of 75 cents for the FY2022 also stood in line with Seet&rsquo s expectations.
 
As Venture expects FY2023 to be a challenging year due to the macro headwinds, Seet has cut his FY2023 and FY2024 earnings by 7% and 11% respectively to reflect the slower growth expected.
 
However, he believes in the longer-term outlook for the company. &ldquo [Venture&rsquo s] management remains confident of its long-term prospects and continues to deepen its partnership with customers to create outstanding innovative products and to scale up its businesses,&rdquo he notes.
 
To this end, Venture remains one of Seet&rsquo s preferred picks for the Singapore technology sector due to its &ldquo excellent execution track record even in tough times&rdquo .
 
Seet&rsquo s unchanged target price is based on an FY2023 P/E of 16.2x.
 
RHB Group Research analyst Alfie Yeo has also kept his &ldquo buy&rdquo call but with a lower target price of $22 from $23.30 previously. Yeo is the only analyst to tweak his target price, which is based on 16x of Venture&rsquo s FY2023 earnings, and 0.5 standard deviation (s.d.) from its historical P/E mean.
 
The lower target price is based on a recalibration of his valuation peg. It has also factored in a reduction of his earnings estimates for the FY2024.
 
&ldquo We re-peg our target P/E to 16x from 19x, which is at a more reasonable +0.5 s.d. from its four-year historical P/E mean (previously +2 s.d.),&rdquo he says.
 
&ldquo As Venture has an environmental, social and governance (ESG) score of three out of four &ndash which is on par with our country median &ndash we ascribe a 0% ESG discount or premium to our target price,&rdquo he adds.
 
Like the rest of his peers, Venture&rsquo s FY2022 earnings came within Yeo&rsquo s full-year estimates. As such, his earnings forecasts for FY2023-FY2024 are &ldquo marginally unchanged&rdquo .
 
&ldquo [However], we did trim [our] FY2024 earnings [estimate] by about 5% to $433 million, and moderated its expected growth rate from to 8% y-o-y from 13% y-o-y,&rdquo he writes.
 
&ldquo Our higher revenue estimate stems from better-than-expected revenue traction and customer demand, while our margin assumptions have been pared down to higher operating costs, i.e. near the current run rate,&rdquo he adds.
 
As Venture&rsquo s FY2022 earnings normalised to pre-pandemic levels, Yeo is remaining &ldquo upbeat&rdquo on the company&rsquo s prospects. &ldquo Management&rsquo s strategy to offer differing solutions remains intact,&rdquo he says.
 
In addition to the changed valuation peg, Yeo&rsquo s lowered target price also factors in his reduced FY2024 earnings estimates.
 
&ldquo Downside risks to our forecasts include decelerating demand in the global environment, resource shortages including component, labour and supply chain constraints,&rdquo he says.
 Useful To Me  Not Useful To Me


elisa28
Veteran
04-Mar-2023 01:14     
 
elisa28 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Buy back 40lots @16.92

MambaFinancial89      ( Date: 03-Mar-2023 20:03) Posted:

Share buybacks today. Love the confidence. 

 Useful To Me  Not Useful To Me
MambaFinancial89
Senior
03-Mar-2023 20:03     
 
MambaFinancial89 About Contact  Quote this Post! Style: Fundamental  
  x 0
  x 0

 Alert Admin 		Share buybacks today. Love the confidence. 
 Useful To Me  Not Useful To Me
tongphlp
Supreme
03-Mar-2023 14:04     
 
tongphlp About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		hopeless

Noob-me      ( Date: 27-Feb-2023 09:20) Posted:

Why the price still drop? Just because dividend remains the same?
 Useful To Me  Not Useful To Me
tongphlp
Supreme
02-Mar-2023 14:00     
 
tongphlp About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		one less headcount on the payroll...cost savings...

MambaFinancial89      ( Date: 02-Mar-2023 13:50) Posted:

Not too concerned as he was not at the company for long...

tongphlp      ( Date: 02-Mar-2023 13:14) Posted:

Venture Corp CFO resigns, company looking for replacement

 
TUE, FEB 28, 2023 - 06:53 PM
 
UPDATED WED, MAR 01, 2023 - 5:22 PM
 

VENTURE Corporation on Tuesday (Feb 28) announced that its chief financial officer (CFO) William Ng has resigned from the company. His last day of service with the company will be Apr 30. 

The 48-year-old has resigned for &ldquo personal reasons&rdquo , a filing to the Singapore Exchange indicated. Ng was appointed to the CFO position on Apr 1, 2022. 

Venture said it is looking for a replacement for the role of CFO, and will make the necessary announcement when a suitable candidate is appointed. 

 

The company said Anthea Ng, who is currently Venture&rsquo s group finance director, will manage the functions and responsibilities of the CFO in the interim. 

William Ng will work closely with her to &ldquo ensure a smooth transition and proper handover of his duties&rdquo , said the company. 

The CFO is responsible for the company&rsquo s finance and accounting functions &ndash including budgeting, financial planning, treasury, cash flow, credit and tax management, and other general corporate and administrative functions, Venture said. 

 

 


 Useful To Me  Not Useful To Me
MambaFinancial89
Senior
02-Mar-2023 13:50     
 
MambaFinancial89 About Contact  Quote this Post! Style: Fundamental  
  x 0
  x 0

 Alert Admin 		Not too concerned as he was not at the company for long...

tongphlp      ( Date: 02-Mar-2023 13:14) Posted:

Venture Corp CFO resigns, company looking for replacement

 
TUE, FEB 28, 2023 - 06:53 PM
 
UPDATED WED, MAR 01, 2023 - 5:22 PM
 

VENTURE Corporation on Tuesday (Feb 28) announced that its chief financial officer (CFO) William Ng has resigned from the company. His last day of service with the company will be Apr 30. 

The 48-year-old has resigned for &ldquo personal reasons&rdquo , a filing to the Singapore Exchange indicated. Ng was appointed to the CFO position on Apr 1, 2022. 

Venture said it is looking for a replacement for the role of CFO, and will make the necessary announcement when a suitable candidate is appointed. 

 

The company said Anthea Ng, who is currently Venture&rsquo s group finance director, will manage the functions and responsibilities of the CFO in the interim. 

William Ng will work closely with her to &ldquo ensure a smooth transition and proper handover of his duties&rdquo , said the company. 

The CFO is responsible for the company&rsquo s finance and accounting functions &ndash including budgeting, financial planning, treasury, cash flow, credit and tax management, and other general corporate and administrative functions, Venture said. 

 

 

 Useful To Me  Not Useful To Me
tongphlp
Supreme
02-Mar-2023 13:14     
 
tongphlp About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

Venture Corp CFO resigns, company looking for replacement

 
TUE, FEB 28, 2023 - 06:53 PM
 
UPDATED WED, MAR 01, 2023 - 5:22 PM
 

VENTURE Corporation on Tuesday (Feb 28) announced that its chief financial officer (CFO) William Ng has resigned from the company. His last day of service with the company will be Apr 30. 

The 48-year-old has resigned for &ldquo personal reasons&rdquo , a filing to the Singapore Exchange indicated. Ng was appointed to the CFO position on Apr 1, 2022. 

Venture said it is looking for a replacement for the role of CFO, and will make the necessary announcement when a suitable candidate is appointed. 

 

The company said Anthea Ng, who is currently Venture&rsquo s group finance director, will manage the functions and responsibilities of the CFO in the interim. 

William Ng will work closely with her to &ldquo ensure a smooth transition and proper handover of his duties&rdquo , said the company. 

The CFO is responsible for the company&rsquo s finance and accounting functions &ndash including budgeting, financial planning, treasury, cash flow, credit and tax management, and other general corporate and administrative functions, Venture said. 

 

 
 Useful To Me  Not Useful To Me
tongphlp
Supreme
27-Feb-2023 11:10     
 
tongphlp About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		beat market consensus = drop
don' t meet consensus = also drop
this is SGX..
clown 

Noob-me      ( Date: 27-Feb-2023 09:20) Posted:

Why the price still drop? Just because dividend remains the same?
 Useful To Me  Not Useful To Me
tongphlp
Supreme
27-Feb-2023 10:45     
 
tongphlp About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		investors lost hope? 

Noob-me      ( Date: 27-Feb-2023 09:20) Posted:

Why the price still drop? Just because dividend remains the same?
 Useful To Me  Not Useful To Me
                                                         First   1-20 of 118   Older>   Last  



ShareJunction Version: 27 Nov 2020 ver- All Rights Reserved. Copyright ShareJunction Pte. Ltd. Disclaimer: All prices from are delayed. ShareJunction does not provide you with any financial advice. We are not into the business of providing any investment advice. See our Terms and Conditions and Privacy Policy of using this website. Data is delayed for varying periods of time depending on the exchange, but for at least 15 minutes. Copyright © SIX Financial Information Ltd. and its licensors. All Rights reserved. Further distribution and use by third parties prohibited. SIX Financial Information and its licensors make no warranty for information displayed and accept no liability for data and prices. SIX Financial Information reserves the right to adapt and/or alter this website at any time without prior notice.

Web design by FoundationFlux. Hosted with Signetique Cloud.